Protalix BioTherapeutics (PLX) Granted Orphan Drug Designation on PRX-102 by the European Commission
Tweet Send to a Friend
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced today that the European Commission granted Orphan Drug Designation (ODD) for pegunigalsidase alfa, or ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE